ERBB2 and triple-negative breast carcinoma: In HER2-low metastatic breast cancer, the ASCENT and DESTINY-Breast04 phase III trials established T-DXd as a strong competitor to sacituzumab govitecan (SG) as a second-line treatment for patients with HER2-low metastatic triple-negative breast cancer (24).